Body composition analysis in late-onset Pompe disease

Molecular Genetics and Metabolism

Volumn 102, Issue 1, 2011, Pages 41-43

  Papadimas, G K ^a   Terzis, G ^a,b   Methenitis, S ^b   Spengos, K ^a   Papadopoulos, C ^a   Vassilopoulou, S ^a   Kavouras, S ^c   Michelakakis, H ^d   Manta, P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c HAROKOPIO UNIVERSITY   (Greece)

^d 'Ag Sophia' Children's Hospital   (Greece)

Author keywords

Bone mineral density; Enzyme replacement therapy; Pompe disease

Indexed keywords

RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; BONE MINERAL; CLINICAL ARTICLE; ENZYME REPLACEMENT; FEMALE; FEMUR NECK; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; MALE; PRIORITY JOURNAL;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; AGED; BODY COMPOSITION; BONE DENSITY; FEMALE; FEMUR NECK; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 78650861049     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.09.002     Document Type: Article

References (16)

1. Kishnani P.S., Steiner R.D., Bali D., Berger K., Byrne B.J., Case L.E., Crowley J.F., Downs S., Howell R.R., Kravitz R.M., Mackey J., Marsden D., Martins A.M., Millington D.S., Nicolino M., O'Grady G., Patterson MC M.C., Rapoport D.M., Slonim A., Spencer C.T., Tifft C.J., Watson M.S. Pompe disease diagnosis and management guideline. Genet. Med. 2006, 8:267-288.
2. van der Ploeg A.T., Reuser A.J. Pompe's disease. Lancet 2008, 372:1342-1353.
3. Katzin L.W., Amato A.A. Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy. J. Clin. Neuromuscul. Dis. 2008, 9:421-431.
4. Mellies U., Lofaso F. Pompe disease: a neuromuscular disease with respiratory muscle involvement. Respir. Med. 2009, 103:477-484.
5. Kishnani P.S., Corzo D., Nicolino M., Byrne B., Mandel H., Hwu W.L., Leslie N., Levine J., Spencer C., McDonald M., Li J., Dumontier J., Halberthal M., Chien Y.H., Hopkin R., Vijayaraghavan S., Gruskin D., Bartholomew D., van der Ploeg A., Clancy J.P., Parini R., Morin G., Beck M., de la Gastine G.S., Jokic M., Thurberg B., Richards S., Bali D., Davison M., Worden M.A., Chen Y.T., Wraith J.E. Recombinant human acid (alpha) glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007, 68:99-109.
6. Merk T., Wibmer T., Schumann C., Krüger S. Glycogen storage disease type II (Pompe disease) - influence of enzyme replacement therapy in adults. Eur. J. Neurol. 2009, 16:274-277.
7. Ravaglia S., Danesino C., Moglia A., Costa A., Cena H., Maccarini L., Carlucci A., Pichiecchio A., Bini P., De Filippi P., Rossi M. Changes in nutritional status and body composition during enzyme replacement therapy in adult-onset type II glucogenosis. Eur. J. Neurol. 2010, 17:957-962.
8. Case L.E., Hanna R., Frush D.P., Krishnamurthy V., DeArmey S., Mackey J., Boney A., Morgan C., Corzo D., Bouchard S., Weber T.J., Chen Y.T., Kishnani PS P.S. Fractures in children with Pompe disease: a potential long-term complication. Pediatr. Radiol. 2007, 37:437-445.
9. Oktenli C. Renal magnesium wasting, hypomagnesemic hypocalcemia, hypocalciouria, and osteopenia in a patient with glycogenosis type II. Am. J. Nephrol. 2000, 20:412-417.
10. van den Berg L.E., Zandbergen A.A., van Capelle C.I., de Vries J.M., Hop W.C., van den Hout J.M., Reuser A.J., Zillikens M.C., van der Ploeg A.T. Low bone mass in Pompe disease. Muscular strength as a predictor of bone mineral density. Bone 2010, 47:643-649.
11. Slonim A.E., Bulone L., Goldberg T., Minikes J., Slonim E., Galanko J., Martiniuk F. Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve 2007, 35:70-77.
12. Kanis J.A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos. Int. 1994, 4:368-381.
13. Gross T.S., Poliachik S.L., Prasad J., Bain S.D. The effect of muscle dysfunction on bone mass and morphology. J. Musculoskelet. Neuronal Interact. 2001, 10:25-34.
14. Case L.E., Kishnani P.S. Physical therapy management of Pompe disease. Genet. Med. 2006, 8:318-327.
15. Skalsky A.J., Abresch R.T., Han J.J., Shin C.S., McDonald C.M. The relationship between regional body composition and quantitative strength in fascioscapulohumeral muscular dystrophy (FSHD). Neuromuscul. Disord. 2008, 18:873-880.
16. Kharti I.A., Chaudhry U.S., Seikaly M.G., Browne R.H., Iannaccone S.T. J. Clin. Neuromuscul. Dis. 2008, 10:11-17.